ArticleScientific reports2016
The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencing.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients.Scientific reports · 2018Trial
- Population genetics and phylogenomic insights into the origin of economically important black pepper (Piper nigrum).American journal of botany · 2026Article
- Stoichiometric constraints for detection of EV-borne biomarkers in blood.Journal of extracellular vesicles · 2025Review
- A critical spotlight on the paradigms of FFPE-DNA sequencing.Nucleic acids research · 2023Review
- Target-enriched long-read sequencing (TELSeq) contextualizes antimicrobial resistance genes in metagenomes.Microbiome · 2022Article
- mRNA Capture Sequencing and RT-qPCR for the Detection of Pathognomonic, Novel, and Secondary Fusion Transcripts in FFPE Tissue: A Sarcoma Showcase.International journal of molecular sciences · 2022Article
- Performance comparison of Agilent new SureSelect All Exon v8 probes with v7 probes for exome sequencing.BMC genomics · 2022Article
- System analysis of the sequencing quality of human whole exome samples on BGI NGS platform.Scientific reports · 2022Article
- Preanalytical Variables and Sample Quality Control for Clinical Variant Analysis.Methods in molecular biology (Clifton, N.J.) · 2022Article
- A customised target capture sequencing tool for molecular identification of Aloe vera and relatives.Scientific reports · 2021Article
- Characterization of DNA lesions associated with cell-free DNA by targeted deep sequencing.BMC medical genomics · 2021Article
- Novel genomic resources for shelled pteropods: a draft genome and target capture probes for Limacina bulimoides, tested for cross-species relevance.BMC genomics · 2020Article
- Update on Cryptosporidium spp.: highlights from the Seventh International Giardia and Cryptosporidium Conference.Parasite (Paris, France) · 2020Review
- Insights into rheumatic diseases from next-generation sequencing.Nature reviews. Rheumatology · 2019Review
- Performance evaluation of commercial library construction kits for PCR-based targeted sequencing using a unique molecular identifier.BMC genomics · 2019Article
- Towards population genomics in non-model species with large genomes: a case study of the marine zooplanktonRoyal Society open science · 2019Article
- Article
- A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia.Research and practice in thrombosis and haemostasis · 2018Article
- Performance evaluation method for read mapping tool in clinical panel sequencing.Genes & genomics · 2018Article
- Library Construction from Subnanogram DNA for Pelagic Sea Water and Deep-Sea Sediments.Microbes and environments · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted capture massively parallel sequencing is increasingly being used in clinical settings, and as costs continue to decline, use of this technology may become routine in health care. However, a limited amount of tissue has often been a challenge in meeting quality requirements. To offer a practical guideline for the minimum amount of input DNA for targeted sequencing, we optimized and evaluated the performance of targeted sequencing depending on the input DNA amount. First, using various amounts of input DNA, we compared commercially available library construction kits and selected Agilent's SureSelect-XT and KAPA Biosystems' Hyper Prep kits as the kits most compatible with targeted deep sequencing using Agilent's SureSelect custom capture. Then, we optimized the adapter ligation conditions of the Hyper Prep kit to improve library construction efficiency and adapted multiplexed hybrid selection to reduce the cost of sequencing. In this study, we systematically evaluated the performance of the optimized protocol depending on the amount of input DNA, ranging from 6.25 to 200 ng, suggesting the minimal input DNA amounts based on coverage depths required for specific applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.